|
18 Companies |
|
18 Products |
|
18 Products |
|
16 Mechanisms of Action |
|
0 Trials |
|
206 News |
|
| 1234» |
- | Aralast NP (alpha 1-antitrypsin) / Omni Bio Pharma, Takeda
Trial withdrawal: A1AT for NMO: Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses (clinicaltrials.gov) - Apr 19, 2019
P1, N=0, Withdrawn, Sponsor: Stanford University
Recruiting --> Withdrawn
- | autologous mesenchymal stem cells / Tianjin Medical University General Hospital
Trial completion, Phase classification: Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders (clinicaltrials.gov) - Oct 17, 2018
P2a, N=15, Completed, Sponsor: Tianjin Medical University General Hospital
Recruiting --> Withdrawn Recruiting --> Completed | Phase classification: P2 --> P2a
- | Trial completion: UROHTLV: Urological Physical Therapy in HTLV-1 With Urinary Symptoms (clinicaltrials.gov) - Oct 5, 2018
P=N/A, N=20, Completed, Sponsor: Hospital Universitário Professor Edgard Santos
Recruiting --> Completed | Phase classification: P2 --> P2a Enrolling by invitation --> Completed
- ||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis (clinicaltrials.gov) - May 30, 2018
P1, N=2, Terminated, Sponsor: American CryoStem Corporation
Enrolling by invitation --> Completed N=100 --> 2 | Trial completion date: Jan 2019 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> May 2018
- Avonex (recombinant IFN-?-1a) / Biogen
Enrollment change: Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX (clinicaltrials.gov) - Apr 12, 2018
P4, N=0, Withdrawn, Sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute
N=100 --> 2 | Trial completion date: Jan 2019 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> May 2018 N=20 --> 0
- | dalfampridine / Generic mfg.
Trial completion, Trial primary completion date: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Jan 9, 2018
P2, N=24, Completed, Sponsor: Johns Hopkins University
N=20 --> 0 Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Jan 2017
- ||| New P3 trial: Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers (clinicaltrials.gov) - Dec 20, 2017
P3, N=26, Completed, Sponsor: GlaxoSmithKline
- || Trial completion: Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers (clinicaltrials.gov) - Dec 20, 2017
P3, N=26, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Jan 2017 Active, not recruiting --> Completed
- | New P1 trial: Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants (clinicaltrials.gov) - Dec 19, 2017
P1, N=25, Completed, Sponsor: GlaxoSmithKline
- | Trial completion: Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants (clinicaltrials.gov) - Dec 19, 2017
P1, N=25, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | aHSCT / University of Calgary
Trial termination: SCT-NMO: Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica (clinicaltrials.gov) - Oct 25, 2017
P1/2, N=3, Terminated, Sponsor: University of Calgary
Active, not recruiting --> Completed Active, not recruiting --> Terminated; recruitment failure
- | Trial completion: Clinical Trial of a Serious Game for Individuals With SCI/D (clinicaltrials.gov) - Oct 17, 2017
P=N/A, N=178, Completed, Sponsor: University of Michigan
Active, not recruiting --> Terminated; recruitment failure Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE) (clinicaltrials.gov) - Aug 31, 2017
P1, N=372, Completed, Sponsor: International Vaccine Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Nov 2016
- dalfampridine / Generic mfg.
Trial primary completion date: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Aug 18, 2017
P2, N=25, Active, not recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Nov 2016 Trial primary completion date: Nov 2016 --> May 2017
- | Trial completion: Natural History of West Nile Virus Infection (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=110, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Trial primary completion date: Nov 2016 --> May 2017 Active, not recruiting --> Completed
- | Omr-IgG-am (intravenous normal human immunoglobulin) / J&J
Trial completion: Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease (clinicaltrials.gov) - Jun 30, 2017
P2, N=2, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Assessment of Patients With Multiple Sclerosis (MS) (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=1388, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Active, not recruiting --> Completed Recruiting --> Completed
- | Enrollment closed, Phase classification, Trial primary completion date: Clinical Trial of a Serious Game for Individuals With SCI/D (clinicaltrials.gov) - May 17, 2017
P=N/A, N=178, Active, not recruiting, Sponsor: University of Michigan
Recruiting --> Completed Recruiting --> Active, not recruiting | Phase classification: P3 --> PN/A | Trial primary completion date: Sep 2018 --> Sep 2017
- ||||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Trial completion, Trial primary completion date: DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (clinicaltrials.gov) - Apr 26, 2017
P3, N=310, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Active, not recruiting | Phase classification: P3 --> PN/A | Trial primary completion date: Sep 2018 --> Sep 2017 Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial completion, Trial primary completion date: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Apr 12, 2017
P2, N=7, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Aug 2015
- || Trial primary completion date: Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis (clinicaltrials.gov) - Feb 15, 2017
P1, N=100, Recruiting, Sponsor: American CryoStem Corporation
Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Aug 2015 Trial primary completion date: Nov 2016 --> Jan 2018
- dalfampridine / Generic mfg.
Trial primary completion date: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Dec 21, 2016
P2, N=25, Active, not recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Nov 2016 --> Jan 2018 Trial primary completion date: Jan 2016 --> Nov 2016
- Trial primary completion date: Clinical Trial of a Serious Game for Individuals With SCI/D (clinicaltrials.gov) - Oct 25, 2016
P3, N=200, Recruiting, Sponsor: University of Michigan
Trial primary completion date: Jan 2016 --> Nov 2016 Trial primary completion date: Apr 2016 --> Sep 2018
- |||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial primary completion date: Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine (clinicaltrials.gov) - Oct 19, 2016
P3, N=793, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Apr 2016 --> Sep 2018 Trial primary completion date: Oct 2008 --> May 2008
- Trial completion: Polio End-game Strategies - Poliovirus Type 2 Challenge Study (clinicaltrials.gov) - May 4, 2016
P4, N=900, Completed, Sponsor: Aga Khan University
Trial primary completion date: Oct 2008 --> May 2008 Not yet recruiting --> Completed
- ||||||| Trial completion: Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) (clinicaltrials.gov) - Feb 27, 2016
P3, N=151, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Completed No longer recruiting --> Completed
- Trial primary completion date: UROHTLV: Urological Physical Therapy in HTLV-1 With Urinary Symptoms (clinicaltrials.gov) - Feb 21, 2016
P=N/A, N=20, Enrolling by invitation, Sponsor: Hospital Universitário Professor Edgard Santos
No longer recruiting --> Completed Trial primary completion date: Dec 2013 --> Dec 2014
- ||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Enrollment change: DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (clinicaltrials.gov) - Feb 18, 2016
P3, N=310, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Trial primary completion date: Dec 2013 --> Dec 2014 N=458 --> 310
- Trial primary completion date: Clinical Trial of a Serious Game for Individuals With SCI/D (clinicaltrials.gov) - Jan 17, 2016
P3, N=200, Recruiting, Sponsor: University of Michigan
N=458 --> 310 Trial primary completion date: Dec 2015 --> Apr 2016
- ||||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial completion: Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (clinicaltrials.gov) - Jan 6, 2016
P3, N=558, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Trial primary completion date: Dec 2015 --> Apr 2016 Active, not recruiting --> Completed
- aHSCT / University of Calgary
Enrollment closed, Enrollment change: SCT-NMO: Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica (clinicaltrials.gov) - Jan 4, 2016
P1/2, N=3, Active, not recruiting, Sponsor: University of Calgary
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=10 --> 3
- | Trial completion: Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM) (clinicaltrials.gov) - Dec 5, 2015
P3, N=60, Completed, Sponsor: University of Sao Paulo
Recruiting --> Active, not recruiting | N=10 --> 3 Active, not recruiting --> Completed
- piracetam / Generic mfg.
Enrollment change, Trial withdrawal: A Randomized, Double Blind, Placebo Controlled Trial L-carnitine and Piracetam in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome (clinicaltrials.gov) - Nov 17, 2015
P3, N=0, Withdrawn, Sponsor: Biolab Sanus Farmaceutica
Active, not recruiting --> Completed N=120 --> 0 | Not yet recruiting --> Withdrawn
- Trial completion, Trial primary completion date: Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults (clinicaltrials.gov) - Nov 11, 2015
P1, N=120, Completed, Sponsor: University Hospital, Ghent
N=120 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Completed | Trial primary completion date: May 2015 --> May 2014
- ||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Enrollment closed: DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (clinicaltrials.gov) - Oct 27, 2015
P3, N=458, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed | Trial primary completion date: May 2015 --> May 2014 Recruiting --> Active, not recruiting
- Trial completion, Phase classification, Trial initiation date, Trial primary completion date: Diarrhea and Bivalent Oral Polio Vaccine Immunity (clinicaltrials.gov) - Oct 15, 2015
P=N/A, N=699, Completed, Sponsor: Centers for Disease Control and Prevention
Recruiting --> Active, not recruiting Withdrawn --> Completed | Phase classification: P3 --> PN/A | Initiation date: May 2012 --> Aug 2012 | Trial primary completion date: Nov 2012 --> Aug 2013
- |||| Trial completion, Trial primary completion date: 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants (clinicaltrials.gov) - Oct 8, 2015
P2, N=824, Completed, Sponsor: Statens Serum Institut
Withdrawn --> Completed | Phase classification: P3 --> PN/A | Initiation date: May 2012 --> Aug 2012 | Trial primary completion date: Nov 2012 --> Aug 2013 Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Sep 2015
- | dalfampridine / Generic mfg.
Enrollment closed: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Oct 2, 2015
P2, N=25, Active, not recruiting, Sponsor: Johns Hopkins University
Active, not recruiting --> Completed | Trial primary completion date: Dec 2015 --> Sep 2015 Recruiting --> Active, not recruiting
- ||||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Trial completion: Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth (clinicaltrials.gov) - Sep 25, 2015
P3, N=177, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Trial completion, Trial primary completion date: The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV) (clinicaltrials.gov) - Sep 16, 2015
P3, N=1200, Completed, Sponsor: Chinese Academy of Medical Sciences
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Oct 2012 --> Sep 2015
- Trial completion, Trial primary completion date: IPV Clinical Trial - The Gambia (clinicaltrials.gov) - Sep 9, 2015
P4, N=1504, Completed, Sponsor: Medical Research Council Unit, The Gambia
Recruiting --> Completed | Trial primary completion date: Oct 2012 --> Sep 2015 Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Apr 2015
- | Trial completion: Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine (clinicaltrials.gov) - Aug 28, 2015
P3, N=738, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed | Trial primary completion date: Jul 2015 --> Apr 2015 Active, not recruiting --> Completed
- Trial completion, Trial primary completion date: Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine (clinicaltrials.gov) - Aug 12, 2015
P4, N=1420, Completed, Sponsor: Fidec Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Apr 2014
- ||| Enrollment closed: 3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants (clinicaltrials.gov) - Jun 25, 2015
P2, N=824, Active, not recruiting, Sponsor: Statens Serum Institut
Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Apr 2014 Recruiting --> Active, not recruiting
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial primary completion date: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. (clinicaltrials.gov) - Jun 12, 2015
P2, N=7, Recruiting, Sponsor: Nihon Pharmaceutical Co., Ltd
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2015 --> Dec 2015
- Avastin (bevacizumab) / Roche
Trial completion: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations (clinicaltrials.gov) - May 29, 2015
P1, N=10, Completed, Sponsor: Johns Hopkins University
Trial primary completion date: Mar 2015 --> Dec 2015 Active, not recruiting --> Completed
- || Trial primary completion date: Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in INDIA (PROVIDE) (clinicaltrials.gov) - May 4, 2015
P1, N=372, Active, not recruiting, Sponsor: International Vaccine Institute
Active, not recruiting --> Completed Trial primary completion date: Feb 2015 --> Jul 2015
- ||||||| Rotarix (rotavirus vaccine) / GSK
Trial completion, Phase classification, Trial primary completion date: Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh (clinicaltrials.gov) - Apr 14, 2015
P3, N=700, Completed, Sponsor: University of Vermont
Trial primary completion date: Feb 2015 --> Jul 2015 Active, not recruiting --> Completed | Phase classification: P1 --> P3 | Trial primary completion date: Jan 2014 --> Oct 2014
- | Enrollment closed: Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine (clinicaltrials.gov) - Apr 3, 2015
P3, N=738, Active, not recruiting, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed | Phase classification: P1 --> P3 | Trial primary completion date: Jan 2014 --> Oct 2014 Recruiting --> Active, not recruiting
- Synflorix (10-valent pneumococcal conjugate vaccine) / GSK, Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK, Rotarix (rotavirus vaccine) / GSK
Enrollment change: Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 Vaccine (clinicaltrials.gov) - Mar 27, 2015
P2, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting N=376 --> 0